Abstract 55P
Background
Routine methods for MSI/dMMR for CRC pts detection are PCR/IHC, however the data on the benefit of ICI in cases with discordant results is limited. The clinical validity of NGS as a promising approach for MSI detection is currently unclear.
Methods
Patients with MSI+ (PCR) or dMMR (IHC) colorectal cancer (CRC) were eligible (NCT06414304). All patients received immune checkpoint inhibitors (ICI) and had pre-treatment FFPE and liquid biopsy (LB) samples available for central MSI/dMMR testing with PCR/IHC (FFPE) and with NGS (Atlas Pro panel) (FFPE and LB).
Results
A total of 32 patients were included, 22 patients with stages II-III received ICI preoperatively, 10 – for advanced disease; 28 were available for response assessment. ORR in ITT population was 46%. Among 4 patients with discordant results (PCR vs IHC), ORR was 0% (p>0.05). In patients with MSI+ FFPE or MSI+ LB by NGS (n=23), ORR was 57% (p>0.05). Among pts with available LB (n=26), ORR was higher when LB samples were MSI+ (56%) vs MSS (25%) with p>0.05. Among MSI+ by NGS (LB) cases two were pMMR by IHC. Both cases had SD and were MSI+ by PCR and NGS (FFPE). None of the patients had MSI+ by NGS (LB) and MSS by PCR. Patients with DC had a median blood MSI burden of 0.07 (range, 0-0.77), whereas median MSI burden of pts with PD was 3.76 (range, 2.44-5.08) (p=0.03). Table: 55P
ORR by MSI analysis via different methods
| NGS (FFPE) | NGS (FFPE) | NGS (LB) | NGS (LB) | ||
| MSI | MSS | MSI | MSS | ||
| IHC (FFPE) | dMMR | 50% (n=16) | 0% (n=1) | 75% (n=12) | 33% (n=3) |
| IHC (FFPE) | pMMR | 0% (n=3) | n=0 | 0% (n=2) | 0% (n=1) |
| PCR (FFPE) | MSI | 45% (n=20) | 100% (n=1) | 44% (n=16) | 33% (n=3) |
| PCR (FFPE) | MSS | n=0 | 0% (n=1) | n=0 | 0% (n=1) |
Conclusions
Patients with MSI+ by PCR may experience different ICI benefits based on IHC status. Patients with MSI+ LB have better ORR. MSI burden analysis in pre-treatment LB samples is associated with better treatment outcomes. Further research is warranted.
Editorial acknowledgement
Clinical trial identification
NCT06414304.
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Human adipose stem cells transfer their mitochondria to breast cancer patient derived organoids increasing drug resistance
Presenter: Martina Marigliano
Session: Cocktail & Poster Display session
Resources:
Abstract
175P - Differential impact of increased neoantigen load on PD-L1 positive immune cell infiltrations in comparison to PD-L1 expression on tumor cells
Presenter: Ashok Kumar Vaid
Session: Cocktail & Poster Display session
Resources:
Abstract
176P - Patient race is a determinant of the impact of Y chromosome loss on survival
Presenter: Suhyeon Choi
Session: Cocktail & Poster Display session
Resources:
Abstract
178P - Clinical correlates and impact of ctDNA levels on detecting distinct genomic alteration in patients with metastatic colorectal cancer
Presenter: Luca Boscolo Bielo
Session: Cocktail & Poster Display session
Resources:
Abstract
179P - Identification of guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer
Presenter: Deepa Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
180P - Unravelling drug resistance in high-grade serous ovarian cancer through clonal dynamics and single-cell heterogeneity analysis
Presenter: Alvaro Ingles Russo Garces
Session: Cocktail & Poster Display session
Resources:
Abstract
181P - Establishment of primary prostate cancer patient-derived organoids to assess PARP inhibitors antitumor activity beyond synthetic lethality
Presenter: Tatiana P. Grazioso
Session: Cocktail & Poster Display session
Resources:
Abstract
182P - METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
Presenter: Maria Virginia Sanchez Becerra
Session: Cocktail & Poster Display session
Resources:
Abstract
183P - SomaVar: A web application for somatic variant storage, annotation and classification
Presenter: Sorin Armeanu-Ebinger
Session: Cocktail & Poster Display session
Resources:
Abstract